Advanced search
1 file | 135.41 KB Add to list

Evaluation of an epigenetic assay for predicting repeat prostate biopsy outcome in African American men

(2019) UROLOGY. 128. p.62-65
Author
Organization
Abstract
OBJECTIVE: To evaluate an epigenetic assay performed on tissue from negative prostate biopsies in a group of African American (AA) men undergoing repeat biopsy, and to compare accuracy for predicting repeat biopsy outcome to prior studies conducted in predominantly Caucasian populations. MATERIALS AND METHODS: The study population consisted of 211 AA men from 7 urology centers across the United States; all of whom were undergoing 12-core transrectal ultrasound-guided repeat biopsy within 30 months from a negative index biopsy. All biopsy cores from the negative index biopsy were profiled for the epigenetic biomarkers GSTP1, APC, and RASSF1 using ConfirmMDx for Prostate Cancer (MDxHealth, Irvine, CA). RESULTS: Upon repeat biopsy, 130 of 211 subjects (62%) had no prostate cancer (PCa) detected and 81 of 211 (38%) were diagnosed with PCa. Of the subjects with PCa, 54 (67%) were diagnosed with Gleason score (GS) <= 6 PCa and 27 (33%) with GS >= 7 disease. For detection of PCa at repeat biopsy, ConfirmMDx sensitivity was 74.1% and specificity was 60.0%, equivalent to prior studies (P = .235 and .697, respectively). For detection of GS >= 7 PCa, sensitivity was 78% and specificity was 53%. The negative predictive values for detection of all PCa and GS >= 7 PCa were 78.8% and 94.2%, respectively. CONCLUSION: In this group of AA men, we successfully validated an epigenetic assay to assess the need for repeat biopsy. Results were consistent with previous studies from predominantly Caucasian populations. Therefore, the ConfirmMDx assay is a useful tool for risk stratification of AA men who had an initial negative biopsy.
Keywords
CANCER, COMPLICATIONS

Downloads

  • Evaluation of an epigenetic.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 135.41 KB

Citation

Please use this url to cite or link to this publication:

MLA
Waterhouse, Robert L., Jr, et al. “Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men.” UROLOGY, vol. 128, 2019, pp. 62–65.
APA
Waterhouse, R. L., Jr, Van Neste, L., Moses, K. A., Barnswell, C., Silberstein, J. L., Jalkut, M., … Van Criekinge, W. (2019). Evaluation of an epigenetic assay for predicting repeat prostate biopsy outcome in African American men. UROLOGY, 128, 62–65.
Chicago author-date
Waterhouse, Robert L, Jr, Leander Van Neste, Kelvin A Moses, Carlton Barnswell, Jonathan L Silberstein, Mark Jalkut, Ronald Tutrone, et al. 2019. “Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men.” UROLOGY 128: 62–65.
Chicago author-date (all authors)
Waterhouse, Robert L, Jr, Leander Van Neste, Kelvin A Moses, Carlton Barnswell, Jonathan L Silberstein, Mark Jalkut, Ronald Tutrone, James Sylora, Ronald Anglade, Myron Murdock, Zvi Shiffman, Todd Vandenberg, Nikhil Shah, Michael Carter, Manuel Krispin, Jack Groskopf, and Wim Van Criekinge. 2019. “Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men.” UROLOGY 128: 62–65.
Vancouver
1.
Waterhouse RL Jr, Van Neste L, Moses KA, Barnswell C, Silberstein JL, Jalkut M, et al. Evaluation of an epigenetic assay for predicting repeat prostate biopsy outcome in African American men. UROLOGY. 2019;128:62–5.
IEEE
[1]
R. L. Waterhouse Jr et al., “Evaluation of an epigenetic assay for predicting repeat prostate biopsy outcome in African American men,” UROLOGY, vol. 128, pp. 62–65, 2019.
@article{8647091,
  abstract     = {OBJECTIVE: To evaluate an epigenetic assay performed on tissue from negative prostate biopsies in a group of African American (AA) men undergoing repeat biopsy, and to compare accuracy for predicting repeat biopsy outcome to prior studies conducted in predominantly Caucasian populations. 
MATERIALS AND METHODS: The study population consisted of 211 AA men from 7 urology centers across the United States; all of whom were undergoing 12-core transrectal ultrasound-guided repeat biopsy within 30 months from a negative index biopsy. All biopsy cores from the negative index biopsy were profiled for the epigenetic biomarkers GSTP1, APC, and RASSF1 using ConfirmMDx for Prostate Cancer (MDxHealth, Irvine, CA). 
RESULTS: Upon repeat biopsy, 130 of 211 subjects (62%) had no prostate cancer (PCa) detected and 81 of 211 (38%) were diagnosed with PCa. Of the subjects with PCa, 54 (67%) were diagnosed with Gleason score (GS) <= 6 PCa and 27 (33%) with GS >= 7 disease. For detection of PCa at repeat biopsy, ConfirmMDx sensitivity was 74.1% and specificity was 60.0%, equivalent to prior studies (P = .235 and .697, respectively). For detection of GS >= 7 PCa, sensitivity was 78% and specificity was 53%. The negative predictive values for detection of all PCa and GS >= 7 PCa were 78.8% and 94.2%, respectively. 
CONCLUSION: In this group of AA men, we successfully validated an epigenetic assay to assess the need for repeat biopsy. Results were consistent with previous studies from predominantly Caucasian populations. Therefore, the ConfirmMDx assay is a useful tool for risk stratification of AA men who had an initial negative biopsy.},
  author       = {Waterhouse, Robert L, Jr and Van Neste, Leander and Moses, Kelvin A and Barnswell, Carlton and Silberstein, Jonathan L and Jalkut, Mark and Tutrone, Ronald and Sylora, James and Anglade, Ronald and Murdock, Myron and Shiffman, Zvi and Vandenberg, Todd and Shah, Nikhil and Carter, Michael and Krispin, Manuel and Groskopf, Jack and Van Criekinge, Wim},
  issn         = {0090-4295},
  journal      = {UROLOGY},
  keywords     = {CANCER,COMPLICATIONS},
  language     = {eng},
  pages        = {62--65},
  title        = {Evaluation of an epigenetic assay for predicting repeat prostate biopsy outcome in African American men},
  url          = {http://dx.doi.org/10.1016/j.urology.2018.04.001},
  volume       = {128},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: